Winfred
Back to Investors
University of Leeds

University of Leeds

Other

The University of Leeds is a large higher education institution and a member of the Russell Group of research-intensive universities.

Website

Portfolio

1

companies

Portfolio companies

LT

LUNAC Therapeutics

LUNAC Therapeutics develops advanced anticoagulants targeting activated Factor XII.

Team

AD

Andy Duley

Director of Commercialisation

Recent investments

Series A
£2.7M

LUNAC Therapeutics raises £2.7m in Series A funding led by Epidarex Capital and University of Leeds to develop novel anticoagulants.

BioTech

Epidarex Capital and the University of Leeds led the Series A round to support the development of next generation anticoagulants.

"There is an urgent need for anticoagulant therapies with reduced bleeding risk. Our research has validated that targeting activated Factor XII may lead to differentiated therapies and a new treatment option for patients."
— Helen Philippou, Scientific Founder
LT
LUNAC Therapeutics— Leeds, UK
EC
University of Leeds
Epidarex Capital + 1 other